Hematopoiesis News Volume 1.00 | Jan 12 2010

    By
    Justin.choi
    -
    0
    22

    Hematopoiesis News 1.00, January 12, 2010.
    In this issue: Science News  |   Current Publications  |   Industry News  |   Policy News  |   EventsSubscribe   |  Unsubscribe

    TOP STORY

    New Target Discovered for Treatment of Cancer
    Researchers at the Swedish medical university Karolinska Institutet have discovered a new way of blocking the formation of blood vessels and halting the growth of tumors in mice. [Karolinska Institutet, Stockholm]

    MethoCult® 
    MethoCult®
    The most published medium for hematopoietic CFC assays
    by STEMCELL Technologies
    		 
     
    TEST YOUR COLONY IDENTIFICATION SKILLSSTEMCELL Technologies Inc
    		 


    SCIENCE NEWS

    Scientists Find New Leukemia Gene Risk Factors
    Researchers have found four new genetic variants that increase the risk of contracting one of the major forms of leukemia, confirming that risk factors for the fatal blood cancer can be inherited. [The European Association for Cancer Research, Nottingham]

    Leukemia Vaccine Being Developed
    A vaccine treatment for Leukemia can be used to stop the disease returning after chemotherapy or bone marrow transplant. [King’s College London, London]

    Johns Hopkins Researchers Say Vaccine Appears to “Mop Up” Leukemia Cells Gleevec Leaves Behind
    Preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia patients taking the drug Imatinib mesylate (Gleevec). [Johns Hopkins University, Baltimore]

    China Surpasses Canada in Stem Cell Advances
    Scientists in China, many of them trained at North American and European universities, published 1,116 articles on stem cells in international peer-reviewed journals in 2008, up from just 37 papers in 2000, says a team at the University of Toronto documenting China’s aggressive bid to become a major player in regenerative medicine. [University of Toronto, Toronto]

    mESC_645x110_v01

    CURRENT PUBLICATIONS

    W41/W41 Blastocyst Complementation: A System for Genetic Modeling of Hematopoiesis
    This study reports a rapid and highly efficient approach to generate mice in which the hematopoietic system is derived from embryonic stem cells. [Blood]

    Loss-Of-Function Additional Sex C ombs Like 1 Mutations Disrupt Hematopoiesis But Do Not Cause Severe Myelodysplasia or Leukemia
    The Additional sex combs like 1 ( Asxl1 ) knockout mice exhibit defects in frequency of differentiation of lymphoid and myeloid progenitors, but not in multipotent progenitors. [Blood]

    Human-Induced Pluripotent Stem Cells from Blood Cells of Healthy Donors and Patients with Acquired Blood Disorders
    Human induced pluripotent stem cells were derived from postnatal human blood cells and the potential of these pluripotent cells for disease modeling was reported. [Blood]

    Shedding of the Endothelial Receptor Tyrosine Kinase Tie2 Correlates with Leukemic Blast Burden and Outcome after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
    The purpose of this study was to elucidate whether the soluble domain of the Tie2 receptor predicts outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. [Ann Hematol]

    Transforming Growth-Interacting Factor Regulates Proliferation and Differentiation of Human Myeloid Leukemia Cells
    Transforming Growth-Interacting Factor has an important role in myelopoiesis and may regulate the balance between proliferation and differentiation. [Mol Oncol]

    Occupational Exposure to Formaldehyde, Hematotoxicity, and Leukemia-Specific Chromosome Changes in Cultured Myeloid Progenitor Cells
    Results suggest that formaldehyde exposure can have an adverse effect on the hematopoietic system and that leukemia induction by formaldehyde is biologically plausible, which heightens concerns about its leukemogenic potential from occupational and environmental exposures. [Cancer Epidemiol Biomarkers Prev]

    The Toll-Like Receptor 7/8 Agonist Resiquimod Greatly Increases the Immunostimulatory Capacity of Human Acute Myeloid Leukemia Cells
    The immunostimulatory effect of the Toll-like receptor (TLR) 7/8 agonist R-848 on human acute myeloid leukemia cells could prove useful for the design of TLR-based immunotherapy for leukemia. [Cancer Immunol Immunother]

    Request A Sample 
    Column-Free Isolation of
    Hematopoietic Stem and Progenitor Cells
    with EasySep®
    		 
     
    REQUEST A SAMPLESTEMCELL Technologies Inc
    		 

    INDUSTRY NEWS

    Amgen Shares Dip On Anemia Drug Concerns
    Shares of Amgen Inc. fell on concerns that the Food and Drug Administration’s plans to re-examine the safety of anemia drugs, which could put more pressure on sales of leading anemia treatments Aranesp and Epogen.

    AMAG Shares Rise on Strong Revenue Outlook for Anemia Drug
    Shares of AMAG Pharmaceuticals Inc. rose as much as 16 percent after the biop harmaceutical company provided a strong fourth-quarter revenue outlook for its injectable anemia medicine Feraheme.

    Cyclacel to Raise Up to $9.5 Million in Registered Direct Offering
    Cyclacel Pharmaceuticals, Inc. announced that it has entered into definitive agreements to raise $7.2 million in gross proceeds, before deducting placement agent fees and other estimated offering expenses, and up to an additional $2.3 million, in a registered direct offering with select institutional investors.

    Ablynx Successfully Generates Nanobodies Against an Ion Channel and Announces New GPCR Program
    Ablynx announced two significant advances achieved within its R&D portfolio. In the first, it has demonstrated the successful generation of functional Nanobodies against an ion channel. In the second, Ablynx has demonstrated in vivo proof-of-concept for a G protein-coupled receptor targeting stem cell mobilization program.

    Aryx Gets FDA Guidance on Blood Clot Drug that Failed Trial
    Aryx Therapeutics Inc. got guidance from the Food and Drug Administration on the continued development of tecarfarin, an anticoagulant that failed a clinical trial last year.

    POLICY NEWS

    Erythropoiesis-Stimulating Agents – Time for a Reevaluation [Food and Drug Administration, United States]

    Notice on P40 Page Limits (NOT-RR-10-002) [National Institutes of Health, United States]

    Academic Research Enhancement Award (Parent R15) (PA-10-070) [National Institutes of Health, United States]

    NIH Broadens Eligibility for NIH Diversity and Re-Entry Supplements (NOT-OD-10-045) [National Institutes of Health, United States]

    Salary Limitation on FY2010 AHRQ Grants, Cooperative Agreements, and Contracts
    (NOT-HS-10-012)     [Agency for Healthcare Research and Quality, United States]

    Technologies and Software to Support Integrative Cancer Biology Research (R43/R44) [Small Business Innovation Research, United States]

    Complete List of Licensed Products and Establishments [Center for Biologics Evaluation and Research, United States]

    EVENTS

    2010 Bone Marrow Transplant Tandem Meetings
    February 24-28, 2010
    Orlando, United States

    36th Annual Meeting of the European Group for Blood & Marrow Transplantation
    March 21-24, 2010
    Vienna, Austria

    12th Biennial CBMTG Conference< BR>April 7-10, 2010
    Vancouver, Canada

    ISSCR 8th Annual Meeting
    June 16-19, 2010
    San Francisco, United States

    XXXIst International Congress of the ISBT in joint cooperation with the 43rd Congress of the DGTI
    June 26-July 1, 2010
    Berlin, Germany

    36th Annual Meeting of the American Society for Histocompatibility & Immunogenetics
    September 26-30, 2010
    Hollywood, United States

    AABB Annual Meeting & TXPO 2010
    October 9-12, 2010
    Baltimore, United States

    52nd ASH Annual Meeting and Exposition
    December 4-7, 2010
    Orlando, United States

    Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy comm unity.


    JOB OPPORTUNITIES

    Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

    Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

    Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

    Data Entry Assistant – Marketing (STEMCELL Technologies)

    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

    Visit here to post your career opportunities.


    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

     

    Learn more about Hematopoiesis News: Archives  |   Events  |   Subscribe  |   Contact Us